Physician profile
Daniel Gutierrez
NPI 1982663654
$1,406.90
in general payments reported to CMS, 2019-2025
12 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $46.36 · 2022: $177 · 2023: $210 · 2024: $339 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $345.76 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $245.38 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $194.03 | 2019-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $178.41 | 2019-2024 | Ingrezza |
| Abbvie INC. | $113.01 | 2024 | |
| Alkermes, INC. | $78.98 | 2019-2020 | |
| Shire North American Group INC | $73.60 | 2019 | |
| Sunovion Pharmaceuticals INC. | $72.94 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $52.23 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $26.24 | 2025 | Fanapt |
| Corium, LLC | $13.57 | 2023 | Azstarys |
| Indivior INC. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.